NCT02101073View on ClinicalTrials.gov

ALX-0061 Phase I Bioavailability Study in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

ALX-0061

single dose, intravenous

BIOLOGICAL

ALX-0061

single dose, subcutaneous

Trial Locations (1)

9470

Zuidlaren

All Listed Sponsors
lead

Ablynx, a Sanofi company

INDUSTRY

NCT02101073 - ALX-0061 Phase I Bioavailability Study in Healthy Volunteers | Biotech Hunter | Biotech Hunter